Roble, Belko & Company, Inc Novo Cure LTD Transaction History
Roble, Belko & Company, Inc
- $583 Million
- Q1 2024
A detailed history of Roble, Belko & Company, Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 20 shares of NVCR stock, worth $342. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20
Previous 20
-0.0%
Holding current value
$342
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NVCR
# of Institutions
277Shares Held
73.2MCall Options Held
1.43MPut Options Held
832K-
Vanguard Group Inc Valley Forge, PA10MShares$172 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.08MShares$156 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA8.86MShares$152 Million0.03% of portfolio
-
State Street Corp Boston, MA3.36MShares$57.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.38MShares$40.8 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.8B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...